NSC 645787
Latest Information Update: 24 Jun 2001
At a glance
- Originator Nonindustrial source
- Class Antineoplastics
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 24 Jun 2001 No-Development-Reported for Cancer in USA (Unknown route)
- 12 Jun 1997 New profile
- 12 Jun 1997 Preclinical development for Cancer in USA (Unknown route)